InvestorsHub Logo
Followers 46
Posts 1362
Boards Moderated 0
Alias Born 08/09/2015

Re: nidan7500 post# 176521

Friday, 12/28/2018 12:49:16 PM

Friday, December 28, 2018 12:49:16 PM

Post# of 460254
LOUISVILLE, KY (NOVEMBER 7, 2014)
Louisville, KY — Neuronetrix has been selected by AnavexLife Sciences Corp. (OTCQB: AVXL) to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer’s disease. Neuronetrix will be utilizing their COGNISION®™ System to measure and analyze cognitive biomarkers in study participants. The ANAVEX 2-73 study incorporates an adaptive design, with an enrollment of 32 mild to moderate Alzheimer’s disease patients.

http://www.cognision.com/neuronetrix-has-been-selected-by-anavex-life-sciences-corp-to-support-the-upcoming-phase-2a-clinical-trial-for-anavex-2-73/

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News